Rep. Richard Hudson

Maddy summaryThe MEGOBARI Act directs the U.S. government to investigate and address democratic backsliding in Georgia. It requires reports within 90 days on Georgian corruption tied to Russian interests, sanctions evasion, and Russian intelligence assets, followed by potential sanctions against Georgian officials deemed responsible for undermining democracy or advancing Russian-style laws. The bill also establishes a U.S. democracy monitoring task force in Georgia and links additional U.S. aid - including trade negotiations, visa liberalization, economic packages, and defense support - to Georgia's progress toward fair elections and a free political environment. These provisions directly affect Georgia's government officials (who could face sanctions) and Georgia's eligibility for U.S. assistance. The bill does not impose new sanctions but mandates U.S. agencies to identify and sanction specific Georgian individuals under existing legal authorities.

Maddy summary# Summary of Tariff Suspensions and Reductions Document This document is a section of U.S. tariff legislation that adds new duty suspensions and reductions to the Harmonized Tariff Schedule of the United States. It contains 120 new tariff items (numbered 9902.19.01 through 9902.20.24) that provide temporary duty-free or reduced-duty status for various goods. Key features of the document: 1. **Content**: The list includes chemical compounds, food ingredients, and specialty materials (such as shelled pine nuts, licorice extract, refined carrageenan, various chemicals like neodymium metal, tungsten concentrate, and numerous organic compounds). 2. **Tariff Treatment**: Most entries are listed as "Free" (meaning duty-free), with a few having small duty rates (e.g., 0.7%, 1.8%, 2.3%, 2.9%, 4.3%). 3. **Effective Period**: All listed suspensions and reductions are effective "On or before 12/31/2025." 4. **Purpose**: These tariff suspensions are intended to support specific industries, reduce costs for manufacturers, or provide temporary relief for certain imported goods. 5. **Technical Details**: Each entry includes the chemical name, CAS number, Harmonized Tariff Schedule code, duty rate, and a brief description of the product. This document represents a legislative amendment to the Harmonized Tariff Schedule, specifically adding new subchapter II of chapter 99 to provide temporary duty relief for these specific items.

Maddy summaryThe Preserving Seniors’ Access to Physicians Act of 2023 increases the Medicare payment adjustment rate for physicians from 1.25% to 4.62%, directly affecting doctors who treat Medicare patients (primarily seniors). It also reduces the funding for the Medicaid improvement fund from $5,796,117,810 to $3,973,117,810. These changes impact Medicare providers and Medicaid programs, with the Medicare adjustment aimed at supporting physicians adjusting to payment changes. The bill does not specify how the Medicaid funding reduction relates to its stated goal of preserving seniors' access to physicians.

Maddy summaryThis bill updates Medicare's physician fee schedule to better align with current healthcare costs and support providers. It extends a key deadline for geographic payment adjustments from 2024 to 2025, increases the rate for payment adjustments from 1.25% to 3%, and extends incentive payments for doctors in alternative payment models (APMs) through 2026. For 2026, it imposes payment reductions (34% for 4-6 years in APMs, 67% for 7+ years) but allows exceptions if providers increased their financial risk compared to 2025. The bill also raises Medicare's budget neutrality threshold to $53 million in 2025 and requires regular updates to cost data (like staff wages and equipment prices) every five years. These changes directly affect Medicare-participating physicians, especially those in APMs, by altering payment calculations and incentives.

Maddy summaryHR 6465, the PLASMA Act, amends Medicare Part D's discount program to create a specific phase-in for plasma-derived specialty drugs. It directly affects Medicare Part D beneficiaries who use these drugs and reach their annual out-of-pocket spending limit. The bill establishes a new "specified plasma-derived product percent" to calculate discounted prices for these drugs, based on whether beneficiaries have already met their out-of-pocket threshold for other Part D drugs. This changes how manufacturers' negotiated prices are discounted for plasma-derived products under the existing program, without creating new benefits or altering coverage.

Maddy summaryHR 6366 delays certain Medicare payment adjustments for physicians and clinical laboratories. It extends the effective year for the "work geographic index" (which sets physician payment rates by location) from 2024 to 2025. The bill also shifts the timeline for implementing reduced Medicare payments for clinical lab tests, moving the phase-in period from 2024-2026 to 2025-2027 and adjusting the reporting years for private payor rate data. These changes directly affect Medicare payments to physicians and clinical laboratories under the Social Security Act. The bill makes technical adjustments to existing payment rules without altering the overall structure of Medicare reimbursement.

Maddy summaryHR 6283, the DRUG Act, regulates pharmacy benefit managers (PBMs) to prevent practices that may increase prescription drug costs for consumers. The bill prohibits PBMs from earning revenue based on drug prices or discounts, requiring them to charge flat dollar service fees instead of fees tied to drug costs. It bans PBMs from steering patients to pharmacies they own or control, mandates equal reimbursement for affiliated and non-affiliated pharmacies, and prohibits charging different fees for the same drug. These provisions apply to group health plans, health insurance issuers, and PBMs, with enforcement beginning for plan years starting January 1, 2026. Violations would result in $10,000 daily penalties and require disgorgement of improperly received payments.

Maddy summaryThe Maximum Pressure Act (HR 6114) is a legislative proposal that would maintain and expand U.S. sanctions against Iran. The bill would codify existing sanctions, require Iran to meet 12 specific conditions before sanctions could be lifted (including ending support for terrorism, releasing hostages, and ending nuclear enrichment), and expand sanctions on Iran's Revolutionary Guard Corps and missile programs. It also establishes new reporting requirements for the U.S. government to monitor Iran's activities and the impact of sanctions. The legislation would require congressional review before any sanctions could be lifted or modified, preventing the executive branch from unilaterally easing restrictions.

Maddy summaryThis bill amends Medicare, Medicaid, and private insurance rules to improve coverage for drugs treating rare diseases (defined as conditions affecting 200,000 or fewer people in the U.S.). It requires coverage for rare disease drug uses supported by peer-reviewed medical literature and not listed as contraindicated in FDA labeling or medical reference guides. Private insurers must provide expedited review processes for denials of such drugs. The changes apply 30 days after enactment, affecting insurers and patients seeking coverage for rare disease treatments.

Maddy summaryHR 5840, the Transportation Security Screening Modernization Act of 2024, simplifies the process for transportation workers to obtain multiple TSA security credentials. It requires the TSA to allow individuals to apply for and renew programs like the TWIC (Transportation Worker Identification Credential) and HAZMAT Endorsement through a single enrollment at any TSA center, with a combined fee lower than separate applications. The bill mandates coordinated expiration dates for all credentials and ensures state-issued commercial driver's licenses reflect the correct HAZMAT endorsement validity. These changes aim to reduce duplication and costs for workers needing multiple security clearances. The TSA must implement these changes within two years and publish details online.